Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Clinical Trial of Futibatinib, an FGFR Inhibitor, in Patients with Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements

ASCO 2020 Highlights

Preliminary results were presented from this phase 2 clinical trial by Lipika Goyal, MD, MPhil, Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, at the 2020 ASCO annual meeting.

The goal of the study is to assess the results of futibatinib, an investigational FGFR inhibitor, for patients with intrahepatic cholangiocarcinoma (CCA) who have FGFR2 fusions or other FGFR2 rearrangements.

Patients with these characteristics were enrolled if they had locally advanced or metastatic, unresectable cancer, had disease progression (getting worse) after 1 or more lines of systemic chemotherapy, and had received no previous therapy with an FGFR inhibitor.

A total of 103 patients enrolled in the study were given 20 mg of futibatinib orally, once daily, until disease progression, drug intolerance, withdrawal of consent, or death.

Promising Results

The following data were available for 67 patients who had 6 months or longer of follow-up. Of these patients, 45% had had 1 previous chemotherapy treatment, 28% had 2 lines of chemotherapy, and 27% of the patients had 3 or more lines of chemotherapy.

Measuring change in tumor from baseline (the start of the study), the objective response rate in these patients was 37.3%, and the disease control rate was 82.1%. Responses were durable, with an average duration of response of 8.3 months.

Side Effects

Serious treatment-related side effects occurred in 10.4% of the patients. The most frequent treatment-related adverse events, each of these occurring in more than 20% of patients, included hyperphosphatemia (81%), diarrhea (37%), dry mouth (33%), alopecia (30%), dry skin (27%), and fatigue (24%). The safety profile was deemed consistent with this drug class of FGFR inhibitors.

The data support the efficacy and safety of futibatinib in patients with CCA and FGFR2 genetic alterations whose disease progressed after chemotherapy.

This clinical trial is closed to new enrollees but a phase 3 clinical trial of futibatinib versus chemotherapy is enrolling new patients at www.ClinicalTrials.gov (NCT04093362).

Recommended For You